Form 4: C4 Therapeutics Director Granted Stock Options

C4 Therapeutics, Inc. reports that Director Utpal Koppikar was granted 62,000 stock options with an exercise price of $4.25, vesting in full by June 24, 2027.

Summary

• Utpal Koppikar, a Director at C4 Therapeutics, Inc., was granted 62,000 stock options on June 24, 2026.
• The stock options have an exercise price of $4.25 per share.
• These options are set to vest and become fully exercisable on the earlier of June 24, 2027, or the next annual stockholder meeting, provided Mr. Koppikar remains on the Board.
• The underlying securities are 62,000 shares of Common Stock.
• The expiration date for these options is June 23, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant operational or financial development.

Positives

• Director granted significant stock options, aligning their interests with shareholders.
• The grant of options suggests confidence in the company's future performance.
• The exercise price of $4.25 indicates a potential upside for the director if the stock price increases.

Negatives

• No immediate financial gain for the company or director from this grant; it's a future potential.
• The vesting schedule ties the benefit to continued service, which is standard but a potential loss if service ends.

Risks

• The value of the stock options is contingent on the future performance of C4 Therapeutics' stock price.
• If the company's stock price does not exceed $4.25, the options may not be exercised.
• Continued service as a Director is a condition for vesting, implying a risk if the director's tenure is cut short.

Future Outlook

The stock options granted to Director Utpal Koppikar vest by June 24, 2027, or the next annual meeting, indicating a forward-looking incentive tied to the company's future stock performance.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term shareholder value creation. This is standard for companies like C4 Therapeutics aiming to attract and retain experienced leadership.

Stakeholder Impact

• Shareholders: The option grant aligns director incentives with potential future stock price appreciation, which can benefit shareholders if the company performs well.
• Employees: This filing does not directly impact employees, but successful company performance driven by management incentives can indirectly benefit them through job security and potential bonuses.
• Management: The director receives a potential financial benefit tied to their continued service and the company's stock performance.

Next Steps

• Utpal Koppikar must remain a Director until at least June 24, 2027, or the next annual meeting, for the options to vest.
• The options can be exercised anytime between their vesting date and June 23, 2036.

Key Dates

Keywords

C4 Therapeutics, CCCC, Form 4, Stock Options, Director Compensation, Beneficial Ownership, Securities Exchange Act, Utpal Koppikar